Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjectsDario Cattaneo, Emilio Clementi, Cristina Gervasoni et al.|Journal of Antimicrobial Chemotherapy|2011Cited by 58
Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse EventsCristina Gervasoni, Dario Cattaneo, Serena Fucile et al.|PLoS ONE|2013Cited by 42
Comparison of the <i>In Vivo</i> Pharmacokinetics and <i>In Vitro</i> Dissolution of Raltegravir in HIV Patients Receiving the Drug by Swallowing or by ChewingDario Cattaneo, Cristina Gervasoni, Sara Baldelli et al.|Antimicrobial Agents and Chemotherapy|2012Cited by 36
Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settingsMarco Pozzi, Emilio Clementi, Dario Cattaneo et al.|European Journal of Clinical Pharmacology|2015Cited by 30
Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patientsDario Cattaneo, Emilio Clementi, Cristina Gervasoni et al.|Pharmacological Research|2011Cited by 21